<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002863'>Myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) are a group of disorders characterised by progressive cytopenias and impaired maturation of haematopoietic cells </plain></SENT>
<SENT sid="1" pm="."><plain>It carries a high mortality due to severe <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> and/or <z:mp ids='MP_0001914'>bleeding</z:mp>, and transformation into <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>Its treatment is largely unsatisfactory except a few favorable reports with low-dose <z:chebi fb="0" ids="28680">cytarabine</z:chebi> therapy, which has recently created a widespread enthusiasm for its use </plain></SENT>
</text></document>